Linsitinib (OSI-906)

Catalog No.S1091

Linsitinib (OSI-906) Chemical Structure

Molecular Weight(MW): 421.49

Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.

Size Price Stock Quantity  
In DMSO USD 190 In stock
USD 170 In stock
USD 270 In stock
USD 720 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

4 Customer Reviews

  • Cancer Res 2013 73, 834-843. Linsitinib (OSI-906) purchased from Selleck.

    OSI-906 prevents the emergence and inhibits growth of established hormone-indendent tumors . A and B, MCF-7 cells were injected s.c. into athymic mice supplemented with 14-day release E2 pellets. Mice with no tumors (A) or bearing tumors ≥ 150 mm3 (B) were randomized to vehicle or OSI-906 (50 mg/kg/day, per os) for 6 weeks. Data are presented as number of tumors formed ; , P = 0.02, Fisher's exact test (A) , or mean tumor volume ± SEM; P < 0.05 versus vehicle, 2-way ANOVA (B). C, tumor-bearing mice from (A) were treated with vehicle or OSI-906 for 3 days. Xenografts were harvested 4 hours after the last dose. Tumor lysates were precipitated with a p-Tyr antibody; p-Tyr pull- downs and tumor lysates were analyzed by immunoblot with the indicated antibodies. D, tumor-bearing mice were imaged before and 4 hours after the initial dose of OSI- 906 by [18 F]FDG -PET. Images from a representative mouse show [18 F]FDG uptake pre- and post–OSI-906 (T-tumor ). Quantification is shown at the bottom.  , P < 0.0001, 2-way ANOVA .

    Cancer Res 2011 71, 6773-84. Linsitinib (OSI-906) purchased from Selleck.

  • (A) MHM cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) or Erlotinib (10 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. EGFR immuno-precipitates were probed with anti-phospho tyrosine antibody. In lanes marked “Serum Starved”, MHM cells were serum starved for 24 hours and stimulated with EGF (10 ng/ml) for 10 minutes. Lysates were collected and immunoblotted with indicated antibodies. (B) OS cell lines and primary OS cells were treated with CP (10 μM) alone, OSI-906 (5 μM) alone or with CP in combination with OSI-906 for 48 hours and whole cell lysates were immunoblotted with the indicated antibodies. (C) MHM and S4 (CP resistant MHM derivatives) cells were treated with CP (10 μM) alone or in combination with OSI-906 (5 μM) for 48 hours and lysates were immunoblotted with indicated antibodies. (D) IGF1 and IGF2 mRNA levels in untreated cells and cells treated with 10 μM CP for 48 hours were determined by qRT-PCR. The level of each mRNA transcript in untreated cells was considered “1.0” and all the other values were plotted relative to it. Shown are the mean results of three experiments, bars, Standard error (SE).

    Oncotarget, 2016, 7(19):27511-26. Linsitinib (OSI-906) purchased from Selleck.

     

    (A) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024, 1µM PPP or 1µM linsitinib for 24h and cell survival was determined by flow cytometry. Results are shown as mean  ± SEM, n=20. (B)CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 15 µM AG1024 (AG) or 1µM linsitinib (L) and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=6). (C) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with a single dose of 1µM PPP and immunoblotted for the expression of phosphorylated IGF1R and IRS-1 (n=4). (D) CLL B cells purified from freshly isolated or freeze-thawed PBMCs from CLL patient samples were treated with 5-15 µM AG1024 and subject to a Western blot analysis using the indicated antibodies. Results are represented as mean±SEM (n=10). Supplementary Figure 1C shows the associated densitometrical analysis after treatment with 15 µM AG1024. (E) CLL B cells purified from freshly isolat ed or freeze-thawed PBMCs from CLL patient samples were treated with 10-500nM rhIGF-1 and immunoblotted for the expression of IGF1R, pIGF1R, pAkt, Akt, pERK and Erk. A representative example from four independent experiments is shown.

    Linsitinib (OSI-906) purchased from Selleck.

Purity & Quality Control

Choose Selective IGF-1R Inhibitors

Biological Activity

Description Linsitinib (OSI-906) is a selective inhibitor of IGF-1R with IC50 of 35 nM in cell-free assays; modestly potent to InsR with IC50 of 75 nM, and no activity towards Abl, ALK, BTK, EGFR, FGFR1/2, PKA etc. Phase 3.
Targets
IGF-1R [1]
(Cell-free assay)
Insulin Receptor [1]
(Cell-free assay)
IRR [1]
(Cell-free assay)
35 nM 75 nM 75 nM
In vitro

OSI-906 inhibits IGF-1R autophosphorylation and activation of the downstream signaling proteins Akt, ERK1/2 and S6 kinase with IC50 of 0.028 to 0.13 μM. OSI-906 enables an intermediate conformation of the target protein through interactions with the C-helix. OSI-906 displays favorable metabolic stability in liver microsomes. OSI-906 fully inhibits both IR and IGF-1R phosphorylation at a concentration of 1 μM. OSI-906 inhibits proliferation of several tumor cell lines including non-small-cell lung cancer and colorectal cancer (CRC) tumor cell line with EC50 of 0.021 to 0.810 μM. [1]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A4-Fuk M2TBfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETuN|RKSzVyPUCuNFI5ODZizszN NGTvWmtUSU6JRWK=
KS-1 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGj0SVFKSzVyPUCuNFM5OzVizszN MX;TRW5ITVJ?
TE-11 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7YdXlKSzVyPUCuNFc5OjJizszN NX3rSJhUW0GQR1XS
EW-1 MnfZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnTHTWM2OD1yLkC4OVg2KM7:TR?= M3jUS3NCVkeHUh?=
HMV-II MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTBwMEi4OFYh|ryP NWrzWWpnW0GQR1XS
COLO-205 NELnbFVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkK2TWM2OD1yLkGwOFU1KM7:TR?= MmPOV2FPT0WU
ES1 M{fJUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml\ZTWM2OD1yLkGwOlk3KM7:TR?= NVvs[IFHW0GQR1XS
GDM-1 MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW3T|lKSzVyPUCuNVM3PzJizszN M4jBRnNCVkeHUh?=
ML-2 MonGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUjJR|UxRTBwMUW4PVYh|ryP MWTTRW5ITVJ?
Saos-2 NX;5[GVVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTRTWM2OD1yLkG2OVI3KM7:TR?= NFXkUYVUSU6JRWK=
NCI-H1355 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkfFTWM2OD1yLkG4NVM2KM7:TR?= MWHTRW5ITVJ?
G-401 NXPxPJJ6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TJdmlEPTB;MD6xPFI{KM7:TR?= MmfYV2FPT0WU
EW-16 NIizdHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWDJR|UxRTBwMUi3O|ch|ryP NEK5XnhUSU6JRWK=
EW-7 NH;1VZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlTXTWM2OD1yLkG4PFgyKM7:TR?= MkezV2FPT0WU
NCI-H727 NVLPfppLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXvJR|UxRTBwMUm3PVQh|ryP NV7qN|YxW0GQR1XS
LCLC-97TM1 NEP4[GpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTBwMkC5OVUh|ryP MX7TRW5ITVJ?
NCI-H650 M1;EWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTBwMkGzPFQh|ryP MYHTRW5ITVJ?
NCI-H2122 NVLOZlNqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHHcpFKSzVyPUCuNlMzQTlizszN MUjTRW5ITVJ?
SK-N-DZ NUjzcoJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1HHR2lEPTB;MD6yN|Y6QCEQvF2= M1LWd3NCVkeHUh?=
HT-29 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXrDdIk6UUN3ME2wMlI1OjR6IN88US=> MYfTRW5ITVJ?
LB771-HNC MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XqU2lEPTB;MD6yOVkyPSEQvF2= NFjWSmJUSU6JRWK=
HT-144 M2\qRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXK1[|BJUUN3ME2wMlI3OTlzIN88US=> NUi5VYgxW0GQR1XS
LAN-6 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIK2Oo9KSzVyPUCuNlY{PDhizszN MUnTRW5ITVJ?
EW-18 NFXEZYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoHjTWM2OD1yLkK3NFAyKM7:TR?= M1jpenNCVkeHUh?=
LS-1034 NHXJb2tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXXJR|UxRTBwMkexN|Ih|ryP Mk[0V2FPT0WU
EW-11 NF3tS4ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4S4V2lEPTB;MD6yPFQ{OiEQvF2= Mm\uV2FPT0WU
SNU-C1 Mn\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTBwMkmzNVMh|ryP MXzTRW5ITVJ?
RS4-11 M1XtTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTBwM{O3OVgh|ryP NYPsXnJqW0GQR1XS
ES4 MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MU\JR|UxRTBwNEGwN|gh|ryP NXnkdJE4W0GQR1XS
COLO-320-HSR NW\neopOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUDEN4U1UUN3ME2wMlQyOzZ6IN88US=> NGXle4ZUSU6JRWK=
NB10 NH:yUGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYnBTFRYUUN3ME2wMlQ2PDN5IN88US=> MXTTRW5ITVJ?
BFTC-905 M2DtNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHFTWM2OD1yLkS2O|U5KM7:TR?= M3\TRXNCVkeHUh?=
A375 NVz5dXRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnPTTWM2OD1yLkS3OlE4KM7:TR?= NY[0eVdEW0GQR1XS
SJRH30 M1zTTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLSTlNKSzVyPUCuOVA5OjJizszN MmrkV2FPT0WU
NOS-1 Mlz1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVjJR|UxRTBwNUKyOlch|ryP MVPTRW5ITVJ?
SIG-M5 M37YSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVjxOHlLUUN3ME2wMlU{PTV5IN88US=> MWrTRW5ITVJ?
DOK NHfLeJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTBwNUW2JO69VQ>? MWLTRW5ITVJ?
NB69 M3r5Omdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn\yTWM2OD1yLkW4NlU4KM7:TR?= MYnTRW5ITVJ?
SK-NEP-1 M{PQb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmS2TWM2OD1yLk[wNlM3KM7:TR?= MoTQV2FPT0WU
SK-MM-2 NGDw[GxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3vNNGlEPTB;MD62OVQ6OSEQvF2= NG\ZXpVUSU6JRWK=
NCI-H358 NGPTeWRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXWwO4dvUUN3ME2wMlY4ODh{IN88US=> M4KySnNCVkeHUh?=
RH-1 MlT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFPtS2hKSzVyPUCuO|Q5PTlizszN MV;TRW5ITVJ?
NH-12 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV;JR|UxRTBwN{[wOFYh|ryP NYHtNnFuW0GQR1XS
TE-12 M1q4N2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml;LTWM2OD1yLke2OFg3KM7:TR?= MmXDV2FPT0WU
COLO-668 NX;3UHBNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mn;CTWM2OD1yLki0OlY3KM7:TR?= MmixV2FPT0WU
PANC-08-13 M2fUb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWrHV3B6UUN3ME2wMlg3Ozd5IN88US=> MkTmV2FPT0WU
HCC2998 M4\oV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MULJR|UxRTBwOEiyOlMh|ryP NWKxUJhyW0GQR1XS
ABC-1 M1Kxbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYjWWXFJUUN3ME2wMlkxOzV{IN88US=> MXTTRW5ITVJ?
ES6 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTBwOUGwOlYh|ryP NGfRVZNUSU6JRWK=
SNU-387 NXjpZ2RQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwOUmzPVMh|ryP NFvxNIdUSU6JRWK=
CMK MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwOUm5Nlkh|ryP MoHqV2FPT0WU
SJSA-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTFwMEO2OVMh|ryP M1f3TnNCVkeHUh?=
SIMA MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYr0fmhIUUN3ME2xMlA3QDJ3IN88US=> NETSdVlUSU6JRWK=
ES3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NELYOpFKSzVyPUGuNVIzQTdizszN NYXoV4tqW0GQR1XS
IGROV-1 NF;1[XBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXy5c|JnUUN3ME2xMlE2PDR2IN88US=> M2fMPHNCVkeHUh?=
MEL-JUSO MkPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWexU29NUUN3ME2xMlE2PzV7IN88US=> MnnqV2FPT0WU
T84 NXLlVnNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPJVmN7UUN3ME2xMlIxQTF2IN88US=> MXXTRW5ITVJ?
CAL-85-1 NFfOWFRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTFwMkOxN|gh|ryP NXjMNYtLW0GQR1XS
RD NYfodoxmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnkdplKSzVyPUGuNlY1PTVizszN MoDzV2FPT0WU
TE-8 Mnf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYrJR|UxRTFwM{G0OlIh|ryP M3TvTHNCVkeHUh?=
L-363 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIDEUXpKSzVyPUGuN|QzODhizszN MlzHV2FPT0WU
EKVX Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTmbVNGUUN3ME2xMlM1PTZ6IN88US=> MkLNV2FPT0WU
SK-MEL-3 NFHYZ2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml3pTWM2OD1zLkS4OVU3KM7:TR?= NVu4cJlQW0GQR1XS
TGBC24TKB MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1TnR2lEPTB;MT61NFE6OyEQvF2= NVH2[YR{W0GQR1XS
NCI-H1770 NWXUfng6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFy2RZlKSzVyPUGuOVEyOTNizszN MlzmV2FPT0WU
HuH-7 M1KzcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfFeWZKSzVyPUGuOlAxQThizszN MlfrV2FPT0WU
HL-60 NGTlR|BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2jzfmlEPTB;MT62OlkzQCEQvF2= NV7DOm45W0GQR1XS
TE-1 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWfJR|UxRTFwN{C5OFUh|ryP M2XFcXNCVkeHUh?=
LC-2-ad M3v3b2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYC2OXl4UUN3ME2xMlc{QDh5IN88US=> M1zpVnNCVkeHUh?=
LB647-SCLC MnvjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX\JR|UxRTFwN{[1PFMh|ryP NVTRTlRIW0GQR1XS
NCI-H2171 NEXDbYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjFXIN7UUN3ME2xMlc4PzF4IN88US=> M2PtcHNCVkeHUh?=
SK-PN-DW MmriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{m2UGlEPTB;MT65NVI6QCEQvF2= M3W5XXNCVkeHUh?=
MC-IXC NVLB[JZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV65[2s6UUN3ME2xMlk5QThizszN NXLPRYZoW0GQR1XS
LS-513 MlPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYi2Rm9tUUN3ME2yMlA2OzB3IN88US=> MUnTRW5ITVJ?
EW-3 Moj4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYDJR|UxRTJwMEm4OFQh|ryP MXPTRW5ITVJ?
OPM-2 M4DtPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PyO2lEPTB;Mj6xNFIh|ryP NX7WPZd1W0GQR1XS
LP-1 MkK2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVjYO2p7UUN3ME2yMlI2QDB5IN88US=> NHT5[HRUSU6JRWK=
LU-134-A MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mn2xTWM2OD1{LkK3O{DPxE1? NIH4PZhUSU6JRWK=
CP66-MEL MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkW5TWM2OD1{LkK5NFE1KM7:TR?= MnH0V2FPT0WU
HCC1143 NGjsPHZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3HeJBKSzVyPUKuOFU{PjhizszN MmjRV2FPT0WU
LOXIMVI NFnlc5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTJwNkCyNUDPxE1? NVrJZoFqW0GQR1XS
TE-10 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3O2NGlEPTB;Mj63NFg{QCEQvF2= Ml;EV2FPT0WU
NCI-H1882 MonBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4rvTmlEPTB;Mj63OVIzPyEQvF2= NWfDSXIxW0GQR1XS
CHP-126 NFX0No1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVKzSZNTUUN3ME2yMlc3OzF5IN88US=> MY\TRW5ITVJ?
NCI-H1623 NXq5OYdYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmDnTWM2OD1{LkmyNFI1KM7:TR?= MYrTRW5ITVJ?
GB-1 M2fobmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnzYTWM2OD1{LkmzOFA1KM7:TR?= MnTuV2FPT0WU
RCC10RGB NFTJWnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYPzPWhbUUN3ME2yMlk2OjhzIN88US=> NIrZNI1USU6JRWK=
NCI-H2141 M1LxZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYPEbYdUUUN3ME2yMlk3QDl4IN88US=> NX;hNZVZW0GQR1XS
GI-ME-N NWXkOHJZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwMEC1OlUh|ryP MWnTRW5ITVJ?
NCI-H526 NHe2dHlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFrtPGJKSzVyPUOuNFQxQDVizszN Mk\tV2FPT0WU
NCI-H747 NWXZW241T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVTJR|UxRTNwMES5PVIh|ryP Ml;HV2FPT0WU
SNU-423 NWHDVIFmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX3JR|UxRTNwMkCzNVMh|ryP MoXiV2FPT0WU
A427 NUixZ5BvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4G4R2lEPTB;Mz6yOVY6QSEQvF2= NX\KSJU5W0GQR1XS
CAL-12T NFnGR5FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFTuTnFKSzVyPUOuOFA4OTNizszN NVzwc49HW0GQR1XS
LU-99A M3fIdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUjJR|UxRTNwNEexNFUh|ryP NGTK[pBUSU6JRWK=
MS-1 M3fRbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUm4ZmhwUUN3ME2zMlU{PDJ7IN88US=> NWfHTolDW0GQR1XS
SK-LU-1 Mkj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGHUdoxKSzVyPUOuO|YzQTVizszN M3WxZXNCVkeHUh?=
SW837 M1;aWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XabmlEPTB;Mz63OlM{OyEQvF2= NFvESndUSU6JRWK=
ES8 NWnFVpN7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvjUZRKSzVyPUOuPFM5PzdizszN MmXaV2FPT0WU
MZ2-MEL MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M176XGlEPTB;Mz65NlA5PiEQvF2= NVu0NYZJW0GQR1XS
TGW MkTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HkXGlEPTB;ND6wNVMyOSEQvF2= MWnTRW5ITVJ?
GP5d M2\EU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVHPZZE3UUN3ME20MlA2OzZ{IN88US=> MlzGV2FPT0WU
BB49-HNC NIXh[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTRwMUWyNVMh|ryP Ml\sV2FPT0WU
NB13 M2G1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX;1[W9ZUUN3ME20MlI3QDh5IN88US=> NHXKVWVUSU6JRWK=
NTERA-S-cl-D1 NXL6OWZnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIKyeINKSzVyPUSuNlg3OTVizszN NH;kUI9USU6JRWK=
NCI-H1648 M4\kR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHj0SVdKSzVyPUSuNlk5OTlizszN MV3TRW5ITVJ?
LCLC-103H NEDvcnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3TqcGlEPTB;ND6zNlE6PSEQvF2= MnKzV2FPT0WU
LS-411N M3HNVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTJR|UxRTRwNES4PFUh|ryP M1e2WXNCVkeHUh?=
NCI-H1092 M3rOPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Moq4TWM2OD12LkS1Olg4KM7:TR?= M1Lq[XNCVkeHUh?=
PANC-10-05 NF\qRo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NILV[GhKSzVyPUSuOlk5PCEQvF2= NULl[YxEW0GQR1XS
DK-MG MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NITrU5NKSzVyPUSuPFA6OzNizszN MXPTRW5ITVJ?
OVCAR-5 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTRwOEGyNlYh|ryP MoS5V2FPT0WU
CAL-39 MkLKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFvHZYpKSzVyPUSuPFc3PyEQvF2= M1P0TnNCVkeHUh?=
TE-441-T NFHLSYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnhRZluUUN3ME20MlkxPTN5IN88US=> M4XGRnNCVkeHUh?=
MOLT-16 NHTUbIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13yfmlEPTB;ND65OVI2OyEQvF2= M{HZcHNCVkeHUh?=
MCF7 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXz3OZgzUUN3ME21MlE1PTF5IN88US=> MV;TRW5ITVJ?
CAPAN-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jGcmlEPTB;NT6yOVcxPyEQvF2= M3fMU3NCVkeHUh?=
PSN1 NETvWWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjzV4ZUUUN3ME21MlI4OjN3IN88US=> MUPTRW5ITVJ?
NCI-H292 NGCyUJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XXUGlEPTB;NT6zNFA1PCEQvF2= NELicolUSU6JRWK=
CPC-N Moj5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4ridGlEPTB;NT6zPVQyQSEQvF2= M13NbnNCVkeHUh?=
DoTc2-4510 MkLES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnvO2dMUUN3ME21MlQ2OzdzIN88US=> MmG3V2FPT0WU
LB1047-RCC MmnxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVe3WXNMUUN3ME21MlU2QTN|IN88US=> M{jzN3NCVkeHUh?=
MHH-ES-1 NFT2NJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M172Z2lEPTB;NT61PVkxPyEQvF2= NWnXWo9SW0GQR1XS
NMC-G1 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2DaUWlEPTB;NT63NFIzPyEQvF2= NUPpRWk{W0GQR1XS
SW1710 MmrQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFjBVFNKSzVyPUWuO|Q4PTFizszN NELmS|NUSU6JRWK=
YAPC NWfj[ZZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MorHTWM2OD13Lke2NlAyKM7:TR?= MWDTRW5ITVJ?
22RV1 M{m1RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEe2N|NKSzVyPUWuPFAxOTlizszN Ml7rV2FPT0WU
COLO-679 NHizT|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnXRTWM2OD13Lki4PVQ5KM7:TR?= MonHV2FPT0WU
TCCSUP NHntU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYryendiUUN3ME21Mlk{OjV7IN88US=> MVnTRW5ITVJ?
C2BBe1 NIPXbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2rT[GlEPTB;NT65N|k4KM7:TR?= MVXTRW5ITVJ?
TE-15 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEXpZZVKSzVyPU[uNFY3ODVizszN M3K0S3NCVkeHUh?=
SCLC-21H MkTSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\CVWlEPTB;Nj6xNFg1OyEQvF2= M4jiWHNCVkeHUh?=
EoL-1-cell MlT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\0bWFKSzVyPU[uNVY2PjNizszN NY\DSIdzW0GQR1XS
NKM-1 MkDCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPpVmFwUUN3ME22MlE3PzFizszN MV\TRW5ITVJ?
NCI-H1304 NH3UcIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHqN3F[UUN3ME22MlI4PDJ6IN88US=> MV3TRW5ITVJ?
NB6 M2XzNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;WSIVKSzVyPU[uNlk3OjJizszN M{nJTXNCVkeHUh?=
NALM-6 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHjrOY1KSzVyPU[uN|MzOyEQvF2= NYXvSmNDW0GQR1XS
NCI-H522 MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYjJR|UxRTZwM{OzNFYh|ryP Mn\zV2FPT0WU
MV-4-11 M3vadmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MliyTWM2OD14LkO3NFc6KM7:TR?= M2P1XnNCVkeHUh?=
LB2241-RCC MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIPXdIhKSzVyPU[uN|g3PjdizszN NETnb3ZUSU6JRWK=
NCI-H1417 NI\oO4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkHPTWM2OD14LkSwPFQ4KM7:TR?= NWHKO|JmW0GQR1XS
HT-1197 NXjNO4xYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIDYdGFKSzVyPU[uOVcyOjJizszN MXrTRW5ITVJ?
P30-OHK MoDsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXzicFhTUUN3ME22MlYzPzdizszN MVHTRW5ITVJ?
ALL-PO MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHK1OWtKSzVyPU[uO|E6OTZizszN MlPEV2FPT0WU
OVCAR-4 M2Dafmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoXiTWM2OD14Lke1OFA2KM7:TR?= M4\GPHNCVkeHUh?=
HCC2157 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PwWWlEPTB;Nj63O|Q4PSEQvF2= MoPVV2FPT0WU
NCI-H838 NFvWcGFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV[1Tnl4UUN3ME22Mlk3PDlizszN M1:1OHNCVkeHUh?=
NCI-H1299 M3HZPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHi3PYRKSzVyPU[uPVcxQSEQvF2= M1;EWHNCVkeHUh?=
SW954 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\temlEPTB;Nz6yNFA3QCEQvF2= MXPTRW5ITVJ?
NCI-H441 Mk\YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEjKSINKSzVyPUeuN|QxPjVizszN MXXTRW5ITVJ?
SK-MEL-2 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G2NmlEPTB;Nz60PFM4OyEQvF2= NVzPTG9kW0GQR1XS
KARPAS-45 NE\xNFlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUDJR|UxRTdwNkW5Nlkh|ryP NXnRNIhCW0GQR1XS
CAL-54 M2\HVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmXnTWM2OD15LkiyPVc4KM7:TR?= M2HKVXNCVkeHUh?=
KYSE-180 MmjPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnLFTWM2OD15Lki4PVQyKM7:TR?= MoPHV2FPT0WU
NCI-H187 NW\Yd4RoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2foNWlEPTB;Nz65OVk1PyEQvF2= M{O4RnNCVkeHUh?=
RT-112 NHi2UGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWDtS5BpUUN3ME24MlA6Pjd5IN88US=> M3qwWHNCVkeHUh?=
NCI-H1437 NWfIV4E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRThwMEm3PVUh|ryP MUTTRW5ITVJ?
SNU-449 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFPreFFKSzVyPUiuNlgzPzJizszN NYL6Z3NrW0GQR1XS
HCC1187 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoPrTWM2OD16LkK5N|kyKM7:TR?= NUXQOFNzW0GQR1XS
NCI-H2030 NHvH[Y9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEfmWVRKSzVyPUiuN|c4OTRizszN NVW1Z2M2W0GQR1XS
HuO-3N1 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRThwM{e4OFQh|ryP Ml7iV2FPT0WU
COLO-792 NXvEN2ZbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRThwNEG1Nlch|ryP NWKzWm51W0GQR1XS
MIA-PaCa-2 NWi3fHZQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7YTWM2OD16Lki1OVA5KM7:TR?= NHPHW21USU6JRWK=
SK-N-FI NYfzdVVmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTlwMESyOUDPxE1? NVezSY5OW0GQR1XS
MMAC-SF M1HJc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{\5eGlEPTB;OT6wPVc2OSEQvF2= MnLBV2FPT0WU
NCI-H28 MojpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnPkTWM2OD17LkGwOFY6KM7:TR?= Moq0V2FPT0WU
ETK-1 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfh[nNzUUN3ME25MlI6QTd2IN88US=> MkfFV2FPT0WU
NCI-H1993 MlHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHjOeWRKSzVyPUmuOFQzPjFizszN M4PmbHNCVkeHUh?=
no-11 NE\xVnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1q1cGlEPTB;OT60O|EzKM7:TR?= MkXFV2FPT0WU
ChaGo-K-1 Mo[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUXjSWhLUUN3ME25MlUyPTh|IN88US=> NWXEeZM2W0GQR1XS
NCCIT MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVnJR|UxRTlwNUOxOlkh|ryP MVLTRW5ITVJ?
SAS M3nJNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2SydGlEPTB;MUCuNlQ5KM7:TR?= MoLyV2FPT0WU
A673 NVPVdJV5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fT[2lEPTB;MUCuN|cxPCEQvF2= M3XYW3NCVkeHUh?=
NCI-H1522 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4qydWlEPTB;MUCuN|cxPyEQvF2= NFLoeohUSU6JRWK=
NCI-H810 Mn\TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\mboQ5UUN3ME2xNE4{QTB5IN88US=> MVPTRW5ITVJ?
IST-MES1 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{XM[mlEPTB;MUCuOFU3PCEQvF2= M4ri[3NCVkeHUh?=
GR-ST MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHPWPWdKSzVyPUGwMlUxOjRizszN M2\hSXNCVkeHUh?=
SUP-T1 NXPaTmZWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIntSo9KSzVyPUGwMlc{OTdizszN MWLTRW5ITVJ?
NB5 M2PsTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmH3TWM2OD1zMD65NFIzKM7:TR?= NWPkb5dLW0GQR1XS
MZ1-PC NH23WXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWrJPGRXUUN3ME2xNE46PTdzIN88US=> NWfyToc5W0GQR1XS
SK-CO-1 Ml\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnXU|ZKSzVyPUGwMlk6OzFizszN M{fFcnNCVkeHUh?=
Capan-2 MnnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnXaTWM2OD1zMT6zNVk5KM7:TR?= MVfTRW5ITVJ?
697 NF3FZ3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\BeFB3UUN3ME2xNU43PzV5IN88US=> NF\yVY9USU6JRWK=
REH MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGLSXGxKSzVyPUGxMlc1PTFizszN MYnTRW5ITVJ?
GI-1 MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfr[pVKSzVyPUGxMlg3OTVizszN M2SyNXNCVkeHUh?=
BB65-RCC NIfQVmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF{LkC5NVYh|ryP MVvTRW5ITVJ?
NCI-H1651 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1nTNWlEPTB;MUKuNlQ4QCEQvF2= MXTTRW5ITVJ?
NCI-H1618 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnNTWM2OD1zMj6zPVc3KM7:TR?= M4XWTXNCVkeHUh?=
NCI-H2081 MoXvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnqbWpKSzVyPUGyMlYyPDFizszN NULld49kW0GQR1XS
GCIY MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYHJR|UxRTF{LkeyNVMh|ryP MnznV2FPT0WU
NY NWLMdnpFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NESxO3VKSzVyPUGzMlA3PDNizszN M1ftXnNCVkeHUh?=
PANC-03-27 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWThTZNLUUN3ME2xN{4xQDB5IN88US=> NWHQVmQyW0GQR1XS
BHY NXm0RoN1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTF|LkKxNlEh|ryP MUfTRW5ITVJ?
SK-OV-3 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGfrfGhKSzVyPUGzMlM4PjNizszN Mn76V2FPT0WU
5637 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEm1WXNKSzVyPUGzMlc4PTlizszN MXrTRW5ITVJ?
LC-1F NFTLZoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRTF2LkCzOVYh|ryP M2XORnNCVkeHUh?=
SNB75 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1eySGlEPTB;MUSuNFM5OyEQvF2= MUPTRW5ITVJ?
CHP-212 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLX[|FVUUN3ME2xOE4xPDZ2IN88US=> MnvhV2FPT0WU
HT-1376 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF\VZWhKSzVyPUG0MlEyOjZizszN MVnTRW5ITVJ?
MONO-MAC-6 MmXsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUjwZ2FKUUN3ME2xOE4yPTB{IN88US=> MoWyV2FPT0WU
CA46 M3vKcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvRb4tKSzVyPUG0MlE5OjdizszN MlrMV2FPT0WU
SCC-15 MmLCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWLjNHJuUUN3ME2xOE42PTh|IN88US=> M1zwVXNCVkeHUh?=
ATN-1 M3zk[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYPJR|UxRTF2Lk[2Nlch|ryP MX;TRW5ITVJ?
NCI-H2405 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlH1TWM2OD1zND64NVU4KM7:TR?= NXXjdm86W0GQR1XS
NCI-H716 NWT3VWJVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml7qTWM2OD1zND64OFk{KM7:TR?= MkHCV2FPT0WU
SW620 NEfzbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX;mdWdkUUN3ME2xOE46ODF2IN88US=> NUHU[Gd2W0GQR1XS
NCI-H226 Mke1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXjJR|UxRTF2LkmwPFUh|ryP Ml6yV2FPT0WU
SW962 M2TyR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF7Ze4xKSzVyPUG0Mlk1OzJizszN MnnhV2FPT0WU
KYSE-150 NEXHc2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4LJRmlEPTB;MUSuPVU2KM7:TR?= MX7TRW5ITVJ?
OCUB-M MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVrH[GVIUUN3ME2xOE46QDh|IN88US=> M4PzUnNCVkeHUh?=
ES7 NUDufG9vT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;nNGlEPTB;MUWuNFk5PCEQvF2= MX\TRW5ITVJ?
SW1463 NX3mPZJqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\obGlEPTB;MUWuOFIzOyEQvF2= NX;3d2RZW0GQR1XS
CAKI-1 MoPPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7aVYZKSzVyPUG1MlU{PDZizszN NEPaZnpUSU6JRWK=
MKN28 NUm3[4VHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2jQO2lEPTB;MUWuOVQ4QSEQvF2= NVO4NmExW0GQR1XS
SW13 Mm\3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HaWmlEPTB;MUWuOlE5KM7:TR?= MWXTRW5ITVJ?
A3-KAW Mk\xS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYfSWnN{UUN3ME2xOU46Pjl5IN88US=> NX3BeVdUW0GQR1XS
LU-65 Ml:4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXBTWM2OD1zNT65O|Y5KM7:TR?= MVfTRW5ITVJ?
Calu-1 NHqwUVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETBU5hKSzVyPUG2MlA{PjhizszN M{n0WHNCVkeHUh?=
ST486 NEjEdG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHPte3BKSzVyPUG2MlA1OzFizszN MWLTRW5ITVJ?
BB30-HNC MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\NTWM2OD1zNj6xNlQ3KM7:TR?= NYfmflZsW0GQR1XS
EGI-1 NHzM[GNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYPJR|UxRTF4LkS0OkDPxE1? NH7mbJlUSU6JRWK=
SH-4 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnNTWM2OD1zNj60O|MyKM7:TR?= MV7TRW5ITVJ?
MN-60 M1jRTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2HTPGlEPTB;MUeuNlI6PyEQvF2= M3T6R3NCVkeHUh?=
MPP-89 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mlu4TWM2OD1zNz6yOFU6KM7:TR?= NULXToE2W0GQR1XS
A2780 M1rQdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFr0NYxKSzVyPUG3MlQyOzlizszN MlXnV2FPT0WU
Daoy NF;qXFNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGH5TWxKSzVyPUG3MlQ3QTVizszN MYfTRW5ITVJ?
NCI-H2126 NWrpPVJCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmTGTWM2OD1zNz60O|cyKM7:TR?= MoP3V2FPT0WU
NCI-H1563 NWTvSlRqT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MU\JR|UxRTF5LkS5NVch|ryP M1fQZ3NCVkeHUh?=
8-MG-BA M1jvZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NWjVNW1uUUN3ME2xO{43PjR6IN88US=> M{GxZXNCVkeHUh?=
786-0 M4nsTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1;S[GlEPTB;MUeuPFM2OyEQvF2= MXPTRW5ITVJ?
AM-38 NGHGPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3P6T2lEPTB;MUeuPVMxPiEQvF2= M1n4TnNCVkeHUh?=
COLO-824 M3;XWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rmbWlEPTB;MUiuOFQ{PiEQvF2= MknNV2FPT0WU
SK-MEL-30 NUe1c2FZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmyTWM2OD1zOD61NFgzKM7:TR?= NHHDW2JUSU6JRWK=
CESS MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVzhZYxnUUN3ME2xPE44PjB7IN88US=> NIezXGFUSU6JRWK=
BL-70 M3\DUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHPmUY1KSzVyPUG4MlgyPTZizszN MmTVV2FPT0WU
NCI-H2170 M3i5PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHLRcWVKSzVyPUG4MlkyPzlizszN NEHoUZBUSU6JRWK=
HT-3 NYGwSIN{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTF6Lkm4N{DPxE1? M3rpXHNCVkeHUh?=
BOKU NFHrdWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIj5S5RKSzVyPUG5MlA{QDFizszN MV3TRW5ITVJ?
HPAF-II NGf4ZnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYfJR|UxRTF7LkOwNVUh|ryP Mly3V2FPT0WU
KGN MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF7LkS3OlUh|ryP Mmm4V2FPT0WU
MC-CAR Mn7VS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3HBfmlEPTB;MUmuOlMyOyEQvF2= M3GwUHNCVkeHUh?=
BHT-101 NHzCUXZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXlbGFzUUN3ME2xPU44PzdizszN NVvpTnIzW0GQR1XS
SW1783 NH31UHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTF7Lke4NFYh|ryP M3\sTHNCVkeHUh?=
KP-N-YN MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVLJR|UxRTJyLkCyOlIh|ryP MmfIV2FPT0WU
LU-165 NFHpbJRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUHJR|UxRTJyLkW1O|Eh|ryP M3znU3NCVkeHUh?=
GOTO M1TKUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4nlcWlEPTB;MkCuOlQ2OSEQvF2= MUfTRW5ITVJ?
EFM-19 NY\vUHNtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojYTWM2OD1{MT6wO|E3KM7:TR?= M17XOXNCVkeHUh?=
CTV-1 NUnmNJgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTJzLkGwOVQh|ryP NGTMb45USU6JRWK=
HEL NGrHeHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml6xTWM2OD1{MT60NlE3KM7:TR?= NHf2RpRUSU6JRWK=
SNU-C2B M1LDd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnWyTWM2OD1{MT60NlYh|ryP MV\TRW5ITVJ?
ECC4 NGHobGlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFj0eYFKSzVyPUKxMlcxPyEQvF2= MYTTRW5ITVJ?
NEC8 MoDqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPLXYV3UUN3ME2yNU45OzZ6IN88US=> MlrYV2FPT0WU
KMOE-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFTSfZdKSzVyPUKxMlg6OjFizszN M1TCN3NCVkeHUh?=
NCI-H524 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVftV4I{UUN3ME2yNk4xQDB6IN88US=> NX3keVhWW0GQR1XS
WSU-NHL M3vkRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVfJR|UxRTJ{LkG1O|ch|ryP MV7TRW5ITVJ?
SF126 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MliwTWM2OD1{Mj6yOFY6KM7:TR?= MlLVV2FPT0WU
HOP-92 NWLUcllST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{jpXmlEPTB;MkKuN|E3PyEQvF2= MoC5V2FPT0WU
CTB-1 NE[0WohIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;UdGlEPTB;MkKuOFY4PyEQvF2= NYn5WINWW0GQR1XS
KYSE-270 NUn5XVZzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHBNFBKSzVyPUKyMlk{PTdizszN NIm5dGpUSU6JRWK=
SK-MEL-24 NU\KS2w2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV;JR|UxRTJ|LkG4O{DPxE1? MUfTRW5ITVJ?
Calu-3 NH7aXJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{PQfWlEPTB;MkOuNlEzQCEQvF2= NVX0[pRnW0GQR1XS
GAMG NFPGT5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3fMdGlEPTB;MkOuNlM3PyEQvF2= M3r5[nNCVkeHUh?=
SW1573 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW2bpdKSzVyPUKzMlc1OTVizszN NIjUVHhUSU6JRWK=
MHH-NB-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3r0W2lEPTB;MkSuNFE6PCEQvF2= NGLwR5FUSU6JRWK=
TK10 NVvOUlg4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFLuR4hKSzVyPUK0MlUxOTNizszN M1yxTHNCVkeHUh?=
LB373-MEL-D M17qXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLoU5RQUUN3ME2yOE43ODZ2IN88US=> MVrTRW5ITVJ?
KALS-1 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTJ2LkezNlch|ryP NEnoRXFUSU6JRWK=
HUTU-80 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmP3TWM2OD1{NT64NFMzKM7:TR?= MnqwV2FPT0WU
HuP-T3 MlfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHzjdHlKSzVyPUK2MlE3PzRizszN NHLs[GZUSU6JRWK=
OE19 NV\Pb2YzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4fqcGlEPTB;Mk[uNlE2OyEQvF2= MWTTRW5ITVJ?
J82 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnXITWM2OD1{Nj6yOFcyKM7:TR?= NFj5WG5USU6JRWK=
DU-4475 NVfPbJdUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFvm[FRKSzVyPUK2MlM5OTlizszN M2rPNXNCVkeHUh?=
DMS-53 M1\kNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3KyS2lEPTB;Mk[uOVE{QCEQvF2= M134R3NCVkeHUh?=
COLO-741 NIrEfVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGftd|FKSzVyPUK2Mlg{PDRizszN MlvlV2FPT0WU
SW48 NFK1TZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYrxS4xbUUN3ME2yOk45QDJizszN NXrUNWczW0GQR1XS
IGR-1 M2[zc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWPJR|UxRTJ4LkmzN|Qh|ryP NYm2RZZrW0GQR1XS
639-V MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX;PVVRDUUN3ME2yO{4xOjR3IN88US=> NWfvd4x1W0GQR1XS
LK-2 Mn;TS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGK2[VJKSzVyPUK3MlQyPDFizszN M2\1VHNCVkeHUh?=
NCI-H2347 NUfDPZd6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmnmTWM2OD1{Nz65Olk6KM7:TR?= MV3TRW5ITVJ?
NCI-H2228 NYe4d2FHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3\MZ2lEPTB;MkiuNFkxPSEQvF2= NFnyWoNUSU6JRWK=
LS-123 MoL0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1LZRWlEPTB;MkiuNVI3OiEQvF2= NYDaUHNyW0GQR1XS
U031 NULHTmxUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVzmb4s6UUN3ME2yPE4zPTJizszN NUn1NJltW0GQR1XS
NCI-H1792 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmnsTWM2OD1{OD60O|IyKM7:TR?= NFvke2pUSU6JRWK=
NCI-H2087 MnWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{\4Z2lEPTB;MkiuO|U2OiEQvF2= MU\TRW5ITVJ?
NCI-H2342 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml:1TWM2OD1{OT61NlA5KM7:TR?= NEX3PYxUSU6JRWK=
SW626 NXf2T|JXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGGwXW9KSzVyPUK5Mlc2PiEQvF2= Mo\xV2FPT0WU
LB2518-MEL M4jCO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XJbGlEPTB;MkmuPFE2KM7:TR?= MYDTRW5ITVJ?
RXF393 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkXJTWM2OD1|MD6wPVUzKM7:TR?= M3v0c3NCVkeHUh?=
LC4-1 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlX4TWM2OD1|MD6zNFkzKM7:TR?= M2DPdHNCVkeHUh?=
NCI-H1694 MnuzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTNyLk[2NlQh|ryP MX3TRW5ITVJ?
K5 NYr0OIxKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlO4TWM2OD1|MD65O|AzKM7:TR?= NVfpWW1tW0GQR1XS
HDLM-2 M1j4bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LTRmlEPTB;M{CuPVczPSEQvF2= Ml35V2FPT0WU
BCPAP MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXaTWM2OD1|MT64N|c6KM7:TR?= MVnTRW5ITVJ?
BC-3 M2rkNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTN{LkG0NFMh|ryP NH3aOldUSU6JRWK=
LB996-RCC MkfMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEmxWGJKSzVyPUOyMlI{PThizszN MWDTRW5ITVJ?
NCI-H2009 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVXw[WZpUUN3ME2zNk41QThzIN88US=> M3rRPXNCVkeHUh?=
HTC-C3 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTN|Lke1NVkh|ryP MmS2V2FPT0WU
LAMA-84 M1XCfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFe1V2hKSzVyPUO0MlQ1ODdizszN MW\TRW5ITVJ?
CCRF-CEM MmfTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M17ueWlEPTB;M{SuOVcyPSEQvF2= NG\s[4xUSU6JRWK=
AN3-CA MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHHp[2VKSzVyPUO1MlA2PjhizszN NX\uWnFqW0GQR1XS
NCI-H1734 Ml7YS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3fXfmlEPTB;M{WuNlU3OSEQvF2= NXTpSGxRW0GQR1XS
Ca-Ski M{HjWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXpeVFKSzVyPUO1MlQyODFizszN NGfRSlFUSU6JRWK=
U-266 M2rHPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXntOnN3UUN3ME2zOU43OTF2IN88US=> NV\yUlhYW0GQR1XS
SBC-5 M3TVU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlvRTWM2OD1|NT63O|gyKM7:TR?= M3zlZnNCVkeHUh?=
GT3TKB MkXPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVPJR|UxRTN5LkGxOUDPxE1? NYXWTHpDW0GQR1XS
MDA-MB-175-VII MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2P6XmlEPTB;M{euNlI1QCEQvF2= M4fLUXNCVkeHUh?=
PFSK-1 NYXTOHRHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkjHTWM2OD1|Nz6yOFM2KM7:TR?= MV7TRW5ITVJ?
IMR-5 NITLO2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfsTWM2OD1|Nz6yOFg4KM7:TR?= NHjmUmVUSU6JRWK=
Daudi M2WzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXTJR|UxRTN5LkO1PVch|ryP NFnnVpZUSU6JRWK=
A498 MmXmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NX71T3V3UUN3ME2zO{44OjF6IN88US=> M13hbXNCVkeHUh?=
SCC-4 M1vHZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTN5Lke4OFMh|ryP NFLLSnBUSU6JRWK=
COLO-680N NX;sZWRJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\0Smk{UUN3ME2zPE4zQDh3IN88US=> MkPIV2FPT0WU
SK-MES-1 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NW[4T4FHUUN3ME2zPE4{OjF3IN88US=> NGHse2NUSU6JRWK=
SR MnryS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIXKbnJKSzVyPUO4MlU1QTVizszN MXrTRW5ITVJ?
LNCaP-Clone-FGC Ml[2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTN6LkW2N|ch|ryP MX3TRW5ITVJ?
SK-HEP-1 M2eyPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4XibWlEPTB;M{iuO|gzOiEQvF2= NF\XenFUSU6JRWK=
BPH-1 MlXyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVnvbIJ5UUN3ME2zPE45OzJ7IN88US=> NW[yUYZUW0GQR1XS
NCI-H1755 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEThUGpKSzVyPUO5MlU5OTdizszN MmC2V2FPT0WU
LXF-289 NEPwc4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NX\KW5ZPUUN3ME2zPU45ODh2IN88US=> Mn7QV2FPT0WU
SW1088 MoXQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7WTWM2OD12MD6yNVA4KM7:TR?= M1PhVXNCVkeHUh?=
MOLT-4 M{DGWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFThWGlKSzVyPUSwMlI6ODFizszN MY\TRW5ITVJ?
AsPC-1 NVPufJZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX3ZOodDUUN3ME20NE41PTh|IN88US=> M3[2c3NCVkeHUh?=
HOP-62 NUjoSmVpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mmj1TWM2OD12MD62OVY5KM7:TR?= NV7EdIVYW0GQR1XS
A172 NIPRbY9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTRyLki1NVEh|ryP NWG1SZF6W0GQR1XS
SN12C Mlr2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2ewPGlEPTB;NECuPVM5PSEQvF2= M3rv[HNCVkeHUh?=
MDA-MB-231 NXH6eoYzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjncoJKSzVyPUSwMlk5QThizszN MUDTRW5ITVJ?
RPMI-2650 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXLJR|UxRTRzLkG1PVMh|ryP MXfTRW5ITVJ?
KYSE-140 M2DPVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmPXTWM2OD12MT64NVI{KM7:TR?= M{LSeHNCVkeHUh?=
KINGS-1 NWmy[3RCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHpTWM2OD12Mj60Olk4KM7:TR?= MlfWV2FPT0WU
HSC-3 M{XrUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTR{Lk[2OlEh|ryP NInzbGFUSU6JRWK=
PC-14 MljYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH7vdmxKSzVyPUSzMlE5QDJizszN NGjVb5ZUSU6JRWK=
COR-L105 NVvKbZF4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTR|Lk[1NFIh|ryP M4fKcnNCVkeHUh?=
BE-13 MnH6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUnJR|UxRTR2LkKzO|Eh|ryP NFS5XnNUSU6JRWK=
NCI-H661 MoLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnTNJY5UUN3ME20OE4zQTV6IN88US=> MkP2V2FPT0WU
IST-MEL1 NILNNYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4HRS2lEPTB;NESuN|U6QSEQvF2= NXXEc2VzW0GQR1XS
HCC1806 NE\ZcopIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUewNJhkUUN3ME20OE42QDd|IN88US=> MV\TRW5ITVJ?
COLO-800 M3PYS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFi1bYFKSzVyPUS0Mlg1PTNizszN NYPo[lZNW0GQR1XS
IST-SL2 NVzJXVJXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXO0WoJ1UUN3ME20OU4yOjR5IN88US=> NYHSV441W0GQR1XS
8305C NF\GSXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2XOV2lEPTB;NEWuN|A6KM7:TR?= NFzPT|VUSU6JRWK=
UACC-62 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NILxeXFKSzVyPUS2MlI5PzVizszN M3TBV3NCVkeHUh?=
COR-L23 NYm3ZlQ5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXvC[|RCUUN3ME20O{4yQTlizszN NHy2OYtUSU6JRWK=
EFE-184 M2ToWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXjJR|UxRTR5LkO4PEDPxE1? MUDTRW5ITVJ?
DMS-114 NHPKUmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3L6RmlEPTB;NEeuOFE1QSEQvF2= NWXZWVB1W0GQR1XS
KYSE-520 NES3doJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVvJR|UxRTR6LkWzNVUh|ryP Mkj1V2FPT0WU
SNG-M NGPsdZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTR7LkSzOEDPxE1? M3H1b3NCVkeHUh?=
A2058 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHISldKSzVyPUS5MlQ5QDVizszN NFjBRppUSU6JRWK=

... Click to View More Cell Line Experimental Data

In vivo OSI-906 inhibits tumor growth in an IGF-1R-driven xenograft mouse model, with 100% TGI and 55% regression at a dose of 75 mg/kg and 60% TGI and no regression at a dose of 25 mg/kg. OSI-906 administration induces different elimination half-lives of itself in dog, rat and mice, the elimination half-lives are 1.18 hours, 2.64 hours and 2.14 hours, respectively. OSI-906 administration at different single dose once-daily in femal Sprague-Dawley rat and femal CD-1 mouse reveal that the Vmax is not dose-proportional to OSI-906 dose. OSI-906 elevates the blood glucose levels at a dose of 25 mg/kg after 12 days administration. OSI-906 administration at a single dose of 75 mg/kg in IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model achieve maximal inhibition of IGF-1R phosphorylation (80%) between 4 and 24 hours with plasma drug concentrations of 26.6-4.77 μM. [1] OSI-906 administered as a single dose of at 60 mg/kg in NCI-H292 xenografts mice inhibits uptake of glucose at 2, 4, and 24 hours post-treatment in vivo. OSI-906 inhibits the growth of tumors in NCI-H292 xenograft mouse model. [2]

Protocol

Kinase Assay:[1]
+ Expand

Protein kinase biochemical assays:

Protein kinase assays are either performed in-house by ELISA-based assay methods (IGF-1R, IR, EGFR and KDR) or at Upstate Inc. by a radiometric method with ATP at 100 µM concentration. In-house ELISA assays use poly(Glu:Tyr) as the substrate bound to the surface of 96-well assay plates and phosphorylation is detected using an antiphosphotyrosine antibody conjugated to horseradish peroxidase. The bound antibody is quantified using ABTS as the peroxidase substrate by measuring absorbance at 405 / 490 nm. All assays use purified recombinant kinase catalytic domains. Recombinant enzymes of human IGF-1R or EGFR are expressed as an NH2-terminal glutathione S-transferase fusion protein in insect cells and are purified in house. IC50 values are determined from the sigmoidal dose–response plot of percent inhibition versus log10 compound concentration. A minimum of three measurements, performed in duplicate, are carried out with in-house assays unless otherwise indicated. OSI-906 at a concentration of 1 µM is profiled versus a panel of kinases using the ProfilerProTM Kinase Selectivity Assay Kit.
Cell Research:[1]
+ Expand
  • Cell lines: MCF7, NCI-H292, Colo-205, HT29, H358, H1703, BxPC3, A673, SW620, DU4475, HepG2 and Hepa-1, RKO 3T3/hulGF-IR and H292 cells
  • Concentrations: 0.02-0.8 μM
  • Incubation Time: 3 days
  • Method: For assays of cell proliferation, cells are seeded into 96-well plates in appropriate media containing FCS 10% and incubated for 3 days in the presence of OSI-906 at various concentrations. Inhibition of cell growth is determined by luminescent quantitation of intracellular ATP content using CellTiterGlo. Data is presented as a fraction of maximal proliferation, calculated by dividing the cellular density in the presence of varying concentrations of OSI-906 by the cellular density of control cells treated with vehicle (DMSO) only.
    (Only for Reference)
Animal Research:[1]
+ Expand
  • Animal Models: IGF-1R-driven full-length human IGF-1R (LISN) xenograft mouse model
  • Formulation: 25 mM tartaric acid
  • Dosages: 25 mg / kg and 75 mg / kg
  • Administration: Orally administrated at once-daily oral dose for 14 days
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 84 mg/mL (199.29 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
30% PEG 400+0.5% Tween 80+5% Propylene glycol
For best results, use promptly after mixing.
30mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 421.49
Formula

C26H23N5O

CAS No. 867160-71-2
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT02057380 Completed Advanced Solid Tumors Astellas Pharma Global Development, Inc.|Astellas Pharma Inc April 2014 Phase 2
NCT02546544 Active, not recruiting Relapsed Ewing Sarcoma|Refractory Ewing Sarcoma University of Oxford|European Organisation for Research and Treatment of Cancer - EORTC|European Commission|Astellas Pharma Inc|Oxford University Hospitals NHS Trust March 2014 Phase 2
NCT01427205 Withdrawn Head and Neck Cancer M.D. Anderson Cancer Center|OSI Pharmaceuticals June 2013 Phase 2
NCT01567384 Withdrawn Cancer|Neoplasms|Tumors Emory University|OSI Pharmaceuticals May 2012 Phase 1
NCT01560260 Completed Carney Complex|Chondrosarcoma|Gastrointestinal Stromal Tumor|Paraganglioma National Cancer Institute (NCI) March 2012 Phase 2
NCT01533246 Completed Adenocarcinoma of the Prostate|Hormone-resistant Prostate Cancer|Recurrent Prostate Cancer|Stage IV Prostate Cancer National Cancer Institute (NCI) February 2012 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Does the inhibitor dissolve in the vehicle (30% PEG400/0.5%Tween 80/5% propylene glycol) or is it a suspension?

  • Answer:

    OSI-906 in 30% PEG400/0.5%Tween 80/5% propylene glycol is a suspension.

IGF-1R Signaling Pathway Map

IGF-1R Inhibitors with Unique Features

Related IGF-1R Products

Tags: buy Linsitinib (OSI-906) | Linsitinib (OSI-906) supplier | purchase Linsitinib (OSI-906) | Linsitinib (OSI-906) cost | Linsitinib (OSI-906) manufacturer | order Linsitinib (OSI-906) | Linsitinib (OSI-906) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID